Curis Stock News

Amalgamated Bank purchased a new stake in Curis, Inc. (NASDAQ:CRIS) in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 15,818 shares of the biotechnology companys stock, valued at approximately $128,000. Several other hedge funds and other institutional investors have also recently made changes []

The trading price of Curis Inc. (NASDAQ:CRIS) closed lower on Friday, November 19, closing at $5.13, -2.29% lower than its previous close. >> 7 Top Picks for the Post-Pandemic Economy

AQR Capital Management LLC purchased a new position in Curis, Inc. (NASDAQ:CRIS) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 65,032 shares of the biotechnology companys stock, valued at approximately $525,000. Several other large investors also recently modified []

In the last trading session, 1.54 million Curis Inc. (NASDAQ:CRIS) shares changed hands as the companys beta touched 2.81. With the companys per share price at $5.61 changed hands at -$0.1 or -1.75% during last session, the market valuation stood at $529.70M. CRISs last price was a discount, traded about -210.16% off its 52-week high Curis Inc. (NASDAQ: CRIS): Performance Report And Growth Forecast Read More »

Curis, Inc. (NASDAQ:CRIS) has received an average rating of Buy from the seven brokerages that are covering the company, MarketBeat reports. Six investment analysts have rated the stock with a buy rating. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $17.63. A []

Curis (CRIS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising ear

Curis (CRIS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising ear

Equities research analysts forecast that Curis, Inc. (NASDAQ:CRIS) will report earnings of ($0.13) per share for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for Curis earnings. The highest EPS estimate is ($0.12) and the lowest is ($0.13). Curis posted earnings of ($0.11) per share during the same quarter last year, []

Curis, Inc. (CRIS) CEO James Dentzer on Q3 2021 Results - Earnings Call Transcript

Curis (CRIS) delivered earnings and revenue surprises of 7.69% and 14.46%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

LEXINGTON, Mass., Oct. 6, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced t

Q2 update from the management team with particular focus on clinical progress on CA-4948 (emavusertib).

Curis' (CRIS) CEO Jim Dentzer on Q2 2021 Results - Earnings Call Transcript

Curis (CRIS) delivered earnings and revenue surprises of -9.09% and -1.68%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Shares of Curis (NASDAQ:CRIS) were flat in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share were up 29.41% year over year to ($0.12), which missed the